These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

212 related articles for article (PubMed ID: 10235581)

  • 1. Relation between limb toxicity and treatment outcomes after isolated limb perfusion for recurrent melanoma.
    Vrouenraets BC; Hart GA; Eggermont AM; Klaase JM; van Geel BN; Nieweg OE; Kroon BB
    J Am Coll Surg; 1999 May; 188(5):522-30. PubMed ID: 10235581
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Regional toxicity after isolated limb perfusion with melphalan and tumour necrosis factor- alpha versus toxicity after melphalan alone.
    Vrouenraets BC; Eggermont AM; Hart AA; Klaase JM; van Geel AN; Nieweg OE; Kroon BB
    Eur J Surg Oncol; 2001 Jun; 27(4):390-5. PubMed ID: 11417986
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Isolated limb perfusion for unresectable melanoma of the extremities.
    Noorda EM; Vrouenraets BC; Nieweg OE; van Geel BN; Eggermont AM; Kroon BB
    Arch Surg; 2004 Nov; 139(11):1237-42. PubMed ID: 15545572
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Repeat isolated limb perfusion with melphalan for recurrent melanoma of the limbs.
    Klop WM; Vrouenraets BC; van Geel BN; Eggermont AM; Klaase JM; Nieweg OE; Kroon BB
    J Am Coll Surg; 1996 Jun; 182(6):467-72. PubMed ID: 8646345
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Factors affecting survival after complete response to isolated limb perfusion in patients with in-transit melanoma.
    Zogakis TG; Bartlett DL; Libutti SK; Liewehr DJ; Steinberg SM; Fraker DL; Alexander HR
    Ann Surg Oncol; 2001 Dec; 8(10):771-8. PubMed ID: 11776490
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Isolated limb perfusion with tumour necrosis factor-alpha and melphalan with or without interferon-gamma for the treatment of in-transit melanoma metastases: a multicentre randomized phase II study.
    Liénard D; Eggermont AM; Koops HS; Kroon B; Towse G; Hiemstra S; Schmitz P; Clarke J; Steinmann G; Rosenkaimer F; Lejeune FJ
    Melanoma Res; 1999 Oct; 9(5):491-502. PubMed ID: 10596916
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Repeat isolated limb perfusion with TNFalpha and melphalan for recurrent limb melanoma after failure of previous perfusion.
    Noorda EM; Vrouenraets BC; Nieweg OE; van Geel AN; Eggermont AM; Kroon BB
    Eur J Surg Oncol; 2006 Apr; 32(3):318-24. PubMed ID: 16412605
    [TBL] [Abstract][Full Text] [Related]  

  • 8. High-dose recombinant tumor necrosis factor alpha in combination with interferon gamma and melphalan in isolation perfusion of the limbs for melanoma and sarcoma.
    Lienard D; Ewalenko P; Delmotte JJ; Renard N; Lejeune FJ
    J Clin Oncol; 1992 Jan; 10(1):52-60. PubMed ID: 1727926
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Factors predictive of acute regional toxicity after isolated limb infusion with melphalan and actinomycin D in melanoma patients.
    Kroon HM; Moncrieff M; Kam PC; Thompson JF
    Ann Surg Oncol; 2009 May; 16(5):1184-92. PubMed ID: 19224289
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Tumour response after hyperthermic isolated limb perfusion for locally advanced melanoma.
    Paulsen IF; Chakera AH; Drejøe JB; Klyver H; Dahlstrøm K; Oturai PS; Mortensen J; Hesse B; Schmidt G; Drzewiecki K
    Dan Med J; 2014 Jan; 61(1):A4741. PubMed ID: 24393586
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Safety and efficacy of isolated limb perfusion in elderly melanoma patients.
    Noorda EM; Vrouenraets BC; Nieweg OE; van Geel AN; Eggermont AM; Kroon BB
    Ann Surg Oncol; 2002 Dec; 9(10):968-74. PubMed ID: 12464588
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Repeated isolated limb perfusion in melanoma patients with recurrent in-transit metastases.
    Deroose JP; Grünhagen DJ; Eggermont AM; Verhoef C
    Melanoma Res; 2015 Oct; 25(5):427-31. PubMed ID: 26110555
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Palliative isolated limb perfusion for advanced limb disease in stage IV melanoma patients.
    Takkenberg RB; Vrouenraets BC; van Geel AN; Nieweg OE; Noorda EM; Eggermont AM; Kroon BB
    J Surg Oncol; 2005 Aug; 91(2):107-11. PubMed ID: 16028280
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Absence of severe systemic toxicity after leakage-controlled isolated limb perfusion with tumor necrosis factor-alpha and melphalan.
    Vrouenraets BC; Kroon BB; Ogilvie AC; van Geel AN; Nieweg OE; Swaak AJ; Eggermont AM
    Ann Surg Oncol; 1999 Jun; 6(4):405-12. PubMed ID: 10379864
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Isolated limb perfusion for melanoma: effectiveness and toxicity of cisplatin compared with that of melphalan and other drugs.
    Thompson JF; Gianoutsos MP
    World J Surg; 1992; 16(2):227-33. PubMed ID: 1561803
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Isolated limb perfusion in primary and recurrent melanoma: indications and results.
    Liénard D; Eggermont AM; Kroon BB; Schraffordt Koops H; Lejeune FJ
    Semin Surg Oncol; 1998; 14(3):202-9. PubMed ID: 9548602
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Prognostic factors for survival after isolated limb perfusion for malignant melanoma.
    Noorda EM; Vrouenraets BC; Nieweg OE; van Geel AN; Eggermont AM; Kroon BB
    Eur J Surg Oncol; 2003 Dec; 29(10):916-21. PubMed ID: 14624788
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Isolated limb reperfusion with tumor necrosis factor and melphalan in patients with extremity melanoma after failure of isolated limb perfusion with chemotherapeutics.
    Bartlett DL; Ma G; Alexander HR; Libutti SK; Fraker DL
    Cancer; 1997 Dec; 80(11):2084-90. PubMed ID: 9392330
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Efficacy of repeat isolated limb perfusions with tumor necrosis factor alpha and melphalan for multiple in-transit metastases in patients with prior isolated limb perfusion failure.
    Grünhagen DJ; van Etten B; Brunstein F; Graveland WJ; van Geel AN; de Wilt JH; Eggermont AM
    Ann Surg Oncol; 2005 Aug; 12(8):609-15. PubMed ID: 15968498
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Isolated limb perfusion with tumor necrosis factor-alpha and melphalan for patients with unresectable soft tissue sarcoma of the extremities.
    Noorda EM; Vrouenraets BC; Nieweg OE; van Coevorden F; van Slooten GW; Kroon BB
    Cancer; 2003 Oct; 98(7):1483-90. PubMed ID: 14508836
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.